Publications & Guidelines

Learn More →

 


 

FibroScan® Approved Indications

The intended use/indications for use for the FibroScan® are as follows:

The FibroScan® system is intended to provide 50Hz shear wave speed measurements and estimates of tissue stiffness as well as 3.5 MHz ultrasound coefficient of attenuation (CAP: Controlled Attenuation Parameter) in internal structures of the body.

FibroScan® is indicated for noninvasive measurement in the liver of 50 Hz shear wave speed and estimates of stiffness as well as 3.5 MHz ultrasound coefficient of attenuation (CAP: Controlled Attenuation Parameter). The shear wave speed and stiffness, and CAP may be used as an aid to clinical management of adult patients with liver disease. Shear wave speed and stiffness may be used as an aid to clinical management of pediatric patients with liver disease.

Shear wave speed and stiffness may be used as an aid to clinical management of pediatric patients with liver disease.

Additionally, the FibroScan® technology complies with all applicable rules governing the level of energy applied and absorbed to the human body, including mechanical indexes and heat dissipation.


Clinical Practice Guidelines

FibroScan® is referenced in Clinical Practice Guidelines:

FibroScan®, patented VCTE technology is the reference for the non-invasive assessment of liver disease in many internationally recognized treatment guidelines, across specific etiologies of Liver Disease

Guideline Etiology of liver disease Reference
AASLD NAFLD Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance from the American Association for the Study of Liver Diseases (link to PDF)
AGA Guidelines HCV, HBV Institute Technical Review on the Role of Elastography in Chronic Liver Diseases (link to PDF)
AASLD/IDSA HCV Recommendations for Testing, Managing and Treating Hepatitis C; When & In Whom to Initiate Antiviral Therapy, AASLD & IDSA Practice Guidelines; www.hcvguidelines.org
EASL HCV EASL Clinical Practice Guidelines: Noninvasive Tests for Evaluation of Liver Disease Severity and Prognosis; Journal of Hepatology 2015
EASL/EASD/EASO NASH Journal of Hepatology 2016 vol 64/1388-1402 http://www.journal-of-hepatology.eu/article/S0168-8278(15)00734- S/fulltext
WHO HCV WHO Guidelines for Screening, Care and Treatment of Persons with Hepatitis C Infection; ISBN 978 92 4 154875 5
WHO HBV Guidelines for the prevention, care, and treatment of persons with chronic hepatitis B infection. 2015 WHO Algorithm of WHO recommendations of the Management of Persons with Chronic Hepatitis B infection (Page xxvi)
WHO HCV & Co-infection Management of HCV & HIV co-infection WHO 2012 HIV/AID treatment. Clinical Protocol for the WHO European Region Chapter 6
Baveno VI Portal Hypertension Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individual care for portal hypertension; 2015 Journal of Hepatology 63, 3 (743-752)
NICE (UK) HCV Diagnosis and Management of Chronic Hepatitis B in Children, Young People Er Adults; guidance.nice.org.uk/cg165

These references represent uses of the FibroScan® in published literature. Echosens does not intend to make any of the specific claims found in these articles. The FibroScan® is a tool to aid in the clinical management of liver disease, and is not intended for the treatment of any specific liver disease or condition.


FibroScan® is appraised in a large body of clinical data.
FibroScan® and its patented VCTE technology are supported by over 1,500 independent peer-reviewed publications.

Visit the Echosens Clinical Library


Fatty Liver Publication Review FibroScan 2016.xlsx

Download 2016 AASLD Abstracts booklet

Download  2016 EASL Abstracts booklet